Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated studies in its campaigns.

Raccontata dawiwo.demilanofinanza.iteluniversal.com.mxdw.comupi.commanager-magazin.debenzinga.comcbsnews.comnu.nlexpansion.comlavanguardia.comchannelnewsasia.com+7 altre